Drug Cost Settlement Promises Billions in Savings

Federal regulators announced a substantial settlement with CVS Caremark, a leading pharmacy benefit manager (PBM), designed to reduce prescription drug expenses for consumers nationwide. This agreement is projected to save patients approximately $4.5 billion over the next decade. The Federal Trade Commission (FTC) had accused PBMs of exacerbating the drug affordability crisis through practices that inflated drug prices and reduced competition for their own financial benefit.

The FTC's complaint highlighted how PBMs profited from manufacturer rebates tied to high-cost drugs, while many patients faced out-of-pocket expenses calculated from these inflated list prices. Under the new settlement, these rebate savings will now be directed to patients, a change heralded by FTC officials as beneficial for consumers.

CVS Caremark stated that the agreement reinforces changes they had already implemented, aiming to ensure affordability. The settlement also includes a significant provision capping monthly insulin costs at $25 for eligible patients. The FTC has reached similar agreements with Express Scripts and is currently reviewing a proposed settlement with Optum Rx, the third PBM involved in the investigation.